KER-012 is under clinical development by Keros Therapeutics and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KER-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KER-012 is under development for the treatment of osteoporosis, osteogenesis imperfecta and pulmonary arterial hypertension. The therapeutic candidate comprises of modified ligand-binding domain of the activin receptor type IIB (ActRIIB) is fused to Fc domain of the human antibody. It acts by targeting activin A and B.
Keros Therapeutics overview
Keros Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. It focuses on study of TGF-ß protein for treatment of development of therapeutics. The company’s product pipeline includes KER-050 for treatment of low blood cell counts, cytopenias, including anemia and thrombocytopenia for patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF); KER-047 for treating fibrodysplasia ossificans progressiva (FOP) and anemia from high hepcidin; KER-012 for treating disorders associated with bone loss, such as osteoporosis and also osteogenesis imperfecta and pulmonary arterial hypertension; and ActRll Variant targeting metabolic diseases. Keros Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of KER-012’s drug-specific PTSR and LoA scores, buy the report here.